We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Novel Fluorescent Technique Detects Early Stage Glaucoma

By LabMedica International staff writers
Posted on 08 May 2017
Print article
Image: The structure of the annexin 5A protein (Photo courtesy of Wikimedia Commons).
Image: The structure of the annexin 5A protein (Photo courtesy of Wikimedia Commons).
A team of British glaucoma researchers used a novel fluorescent microscopy technique to rapidly diagnose the disease at a very early stage.

Retinal cell apoptosis occurs in many ocular neurodegenerative conditions including glaucoma - the major cause of irreversible blindness worldwide. Investigators at University College London employed a new imaging technique called DARC (detection of apoptosing retinal cells), which until now had only been demonstrated in animal models. The investigators determined if the protein annexin 5 labeled with the fluorescent dye DY-776 (ANX776) could be used safely in humans to identify retinal cell apoptosis.

Annexin A5 is a cellular protein in the annexin group, which is used as a non-quantitative probe to detect cells that have expressed phosphatidylserine (PS) on the cell surface, an event found in apoptosis as well as other forms of cell death.

In the study, eight patients with glaucomatous neurodegeneration and evidence of progressive disease, and eight healthy subjects were randomly assigned to intravenous ANX776 doses of 0.1, 0.2, 0.4, and 0.5 milligrams in an open-label, phase I clinical trial. In addition to assessing the safety, tolerability, and pharmacokinetics of ANX776, the study aimed to explore whether DARC could successfully visualize individual retinal cell apoptosis in vivo in humans, with the DARC count defined as the total number of unique ANX776-labelled spots.

The results demonstrated that retinal cell apoptosis could be identified in the human retina with increased levels of activity in glaucomatous neurodegenerative disease. DARC enabled retinal cell apoptosis to be identified in the human retina using ANX776. Single annexin-labelled cells were visualized in a dose-dependent pattern up to six hours after injection. The DARC count was significantly higher in glaucoma patients compared to healthy controls, and was significantly greater in patients who later showed increasing rates of disease progression, based on optic disc, retinal nerve fiber layer, or visual field parameters. Additionally, the DARC count significantly correlated with decreased central corneal thickness and increased cup-disc ratios in glaucoma patients and with increased age.

ANX776 was found to be safe and well tolerated with no serious adverse events, and a short half-life (10 to 36 minutes).

First author Dr. Francesca Cordeiro, professor of retinal neurodegeneration and glaucoma studies at University College London, said, "Detecting glaucoma early is vital as symptoms are not always obvious. Although detection has been improving, most patients have lost a third of vision by the time they are diagnosed. Now, for the first time, we have been able to show individual cell death and detect the earliest signs of glaucoma. While we cannot cure the disease, our test means treatment can start before symptoms begin. In the future, the test could also be used to diagnose other neurodegenerative diseases."

The DARC study was published in the April 26, 2017, online edition of the journal BRAIN.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.